The role of supplementary vitamin D in treatment course of pulmonary tuberculosis
| Autor: | Ayman Ibrahim Baess, Essam Gouda Hassanein, Ahmad Madi Yossef, Enas Elsayed Mohamed, Eman Tayae EL-Sayed |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
lcsh:RC705-779 medicine.medical_specialty business.industry Pulmonary tuberculosis lcsh:Diseases of the respiratory system Pyrazinamide medicine.disease vitamin D deficiency 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Immune system Internal medicine medicine Vitamin D and neurology Sputum 030212 general & internal medicine medicine.symptom Vitamin D Intramuscular injection business Ethambutol Rifampicin medicine.drug |
| Zdroj: | Egyptian Journal of Chest Disease and Tuberculosis, Vol 65, Iss 3, Pp 629-635 (2016) |
| ISSN: | 0422-7638 |
| Popis: | Background Vitamin D insufficiency/deficiency is associated with impaired immune function and increased risk of active pulmonary tuberculosis (TB). Objectives To evaluate the role of vitamin D as supplementary treatment with the first line anti-tuberculous drugs (rifampicin, izoniazide, ethambutol and pyrazinamide) in treatment course of patients with active pulmonary tuberculosis. Methods We conducted a case-control study in El Maamora chest hospital, Alexandria governorate, Egypt, including 60 adult patients with active pulmonary TB of 30 patients each. Patients in group I (cases) received vitamin D (200,000 IU) intramuscular injection once besides anti-tuberculous drugs, while patients in group II (controls) were randomly selected from the hospital registry who received the first line anti-tuberculous treatment only. The primary outcome was evaluation of conversion time of sputum smear. The secondary outcome was clinical improvement as assessed by TB score. Measurements and main results Mean ± SD age of all patients was 41.55 ± 14.91 years. The study included 44 (73.3%) males and 16 (26.7%) females. Vitamin D deficiency/insufficiency was detected in 54 (90%) patients. Comparing the two groups, there was a rapid decline in sputum conversion time and severity classes of TB score in group I compared to group II ( p p = 0.02, respectively). No complications secondary to supplementary vitamin D were met all through the study. Conclusion Vitamin D accelerates the improvement observed in vitamin D supplemented TB therapy. Vitamin D is safe when added to anti-tuberculous drugs. Vitamin D deficiency/insufficiency is common among TB patients. Further studies are required to validate this observation and define a cut off of vitamin D level to prevent immunological alterations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|